Meet Jan-Åke Gustafsson by Angela Hopp ('00) When Gov. Rick Perry announced at a recent news conference on campus that the state would give the University of Houston a multimillion-dollar grant—its first through the Texas Emerging Technology Fund (ETF)—some members of the audience swelled with pride, others exhaled after months of hard work to make it happen, and all of them watched one man accept the school’s colors and the planet of responsibility that comes with them. Jan-Åke Gustafsson, an internationally renowned hormones expert, already had accepted an appointment over the summer to expand his revolutionary research efforts at UH. But, the $5.5 million grant from the state sealed the deal and will enable his team to create next-generation pharmaceuticals and medical technologies at a world-class center to be established by UH and The Methodist Hospital Research Institute (TMHRI). The recruitment of Gustafsson, Foreign Honorary Member of the National Academy of Sciences and the American Academy of Arts and Sciences and member of the Nobel Assembly, represents a significant milestone in fulfilling President Renu Khator’s vision for the university, which includes a UH Health Initiative that will expand UH’s presence and partnerships in the Texas Medical Center. “We are delighted to have Dr. Gustafsson join our faculty as a key leader in our biomedical initiative,” says Khator. “He was courted by Ivy League institutions and determined the University of Houston offered the best opportunity to advance his research. He will play an important role in our quest for top-tier national recognition.” The governor calls reaching top-tier status “a journey,” adding that “the University of Houston has taken a large step in that direction today to be a Tier-One institution.” “This journey has taken the University of Houston to heights that maybe, some years ago, people might not have thought were in reach,” says Perry. “But, as every day goes by, it becomes more and more apparent to folks that this institution is headed to the forefront of not only higher education in the state of Texas, but, particularly, on the forefront of the commercialization of technology. And, the horizon is limitless.”
His World-Leading Research Targets Deadly Cancers
Gustafsson, who holds a Ph.D. and M.D., will head the Center for Nuclear
Receptors and Cell Signaling. He will teach at the Department of Biology and
Biochemistry and the Department of Chemistry in the College of Natural Sciences
and Mathematics. He also will be a member of TMHRI. His appointment is the first strategic hire for the UH Health Initiative and
follows strategic hires for other UH “research clusters” since Khator arrived
last year. His appointment includes a fifteen-member research team, which helps
to “fast track” progress and innovation coming out of the new center. “Often, new ideas and breakthroughs occur at the borders of scientific
disciplines,” Gustafsson says. “It’s when they come together in the border zone that you can have new breakthroughs, new ideas—you can advance the field.” Gustafsson says he looks forward to building a state-of-the-art research
center, which will focus on a “medically very important field.” “The concentration of outstanding scientists at UH, TMHRI, and in the Houston
area in general, including the Texas Medical Center, provides unique
possibilities for cutting-edge translational research with great clinical and
commercial potential,” he adds. Stuart Dryer, John and Rebecca Moores Professor of Biology and Biochemistry
and chair of the UH Department of Biology and Biochemistry, says Gustafsson will
“fit in beautifully with the existing strengths of the department and will
provide leadership in a number of new interdisciplinary ventures.” “For me, this is the most exciting thing that has happened at the University
of Houston since I arrived eleven years ago,” Dryer notes. Gustafsson is revered worldwide for his translational research on nuclear
receptors, a class of proteins found in cell nuclei that capture hormone
molecules and interact with and control the expression of genes. Research in the
field is vital in developing treatments for such diseases as cancer and
diabetes. Here’s how nuclear receptors work: Each receptor in the cell’s nucleus has a
cavity shaped just so that a hormone molecule can fit inside. Once wedded to the
hormone, the nuclear receptor’s outer surface changes, depending upon the type
of hormone housed within. Then, other proteins recognize the receptor’s surface
structure and join in a chain reaction. This hormone-controlled process
influences expression of genetic information and the development and metabolism
of an organism. “Nuclear receptors provide the lock that the key of your hormones fits in.
They allow your DNA to be read and expressed,” explains B. Montgomery “Monte”
Pettitt (’75, ’75, Ph.D. ’80), Hugh Roy and Lillie Cranz Cullen Professor in
Chemistry and professor of computer science, physics, biology, and biochemistry.
“Gustafsson discovered a major estrogen receptor protein and has worked in a
variety of application areas, including cancer. We are very fortunate to have
him and his team relocating to UH.” Gustafsson’s research group at the Karolinska Institutet in Stockholm,
Sweden, in the mid-1990s discovered the existence of a previously unknown
estrogen receptor that plays a pivotal role in the function of the brain, lungs,
and immune system. Today, drugs are being developed to stimulate that receptor, named ER-beta,
to battle a number of diseases, including breast, prostate, and lung cancers. In
some instances, the abnormal cell division that creates cancerous tumors can be
slowed down or stopped by stimulating the receptor. The ETF’s Research Superiority Acquisition grants are intended to bring the
best and brightest researchers in the world to Texas. Over the summer, UH and TMHRI applied for a superiority grant to attract
Gustafsson and establish the center, a research enterprise aimed at better
understanding the relationship between nuclear receptors and disease detection,
management, and treatment. Don Birx, UH vice president for research, says he
envisions Gustafsson’s research program to span the region, by partnering with
medical institutions, and to rapidly establish international prominence. Over the decades, Gustafsson has developed many fruitful relationships with
other prominent Houston researchers. Among them is Bert O’Malley, professor of
molecular and cellular biology at Baylor College of Medicine and recent
recipient of the National Medal of Science. “The recruitment of an outstanding scientist such as Dr. Gustafsson to the
University of Houston represents a landmark achievement in biologic development
at UH. He will bring an internationally recognized team to study estrogen action
in normal and diseased tissues that will have a wide impact across other
university departments,” says O’Malley. The potential for commercialization was pivotal to UH’s ETF grant
application, Birx explains. “The approach we take with the ETF is different than you might expect from
government. It’s not about a giveaway. It uses incentives, investments that lead
to innovation here in Texas,” Perry says. “We’re about finding marketable
technologies, fueling those innovations . . . starting ventures that turn a
profit. You might say that the old academic motto of ‘publish or perish’ is
being replaced by ‘patent or perish.’” Perry says the UH grant is “the latest example of our efforts to find great
ideas born in university laboratories, invest in them to generate the products
that can ultimately create jobs, turn a profit—keep our state’s economy
going.” Gustafsson has a solid commercialization track record, and he is co-founder
of KaroBio AB, a biotechnology company on the Karolinska campus, along with Dr.
John D. Baxter, who joined TMHRI last year. “Of today’s existing drugs, 20 percent are actually drugs that affect, as
keys, these nuclear receptors,” Gustafsson explains. “It’s a vast area for
further development.” Dr. Michael Lieberman, director of TMHRI, says the center represents a
substantial collaboration between UH and Methodist. Birx says Gustafsson’s team will provide leadership aligned with UH’s mission
“to engage the major issues of our time in ways that significantly impact the
lives of those around the world.” “His scientific and commercialization expertise will capitalize on and serve
Texas’ desire to lead in medical discovery—particularly in cancer diagnostics
and therapy,” Birx says. Gustafsson says nuclear receptors are a natural avenue for commercialization,
because “if you are skillful and use opportunities, you can use chemicals” to
affect the activity of genes. His work on other nuclear hormone receptors lends itself to new treatments
for metabolic syndrome, including atherosclerosis, type 2 diabetes, and
nonalcoholic hepatic steatosis, also known as fatty liver. He also has found
evidence that the roles played by estrogen receptors and nuclear hormone
receptors in the brain may be manipulated to treat neurodegeneration,
Parkinson’s disease, Lou Gehrig’s disease, depression, and other mood
disorders. Researcher Margaret Warner, who has worked with Gustafsson for more than
twenty years, and up to fifteen others on his Karolinska team are to join him at
UH. Warner will be a faculty member in UH’s Department of Biology and
Biochemistry. Gustafsson says he’ll vigorously recruit others in the months to
come. “My goal, or our goal, is to have a sizeable center in place in one to two
years, and I think that can be done,” he says.
Strategic Hire
The Workings of Nuclear Receptors
Emerging Technology Fund Grant
Research Commercialization
The Team
GUSTAFSSON’S Selected Honors
Regents Message